{"id":"NCT00802529","sponsor":"Imperial College London","briefTitle":"Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease","officialTitle":"Effectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2009-04","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2008-12-05","resultsPosted":"2016-10-24","lastUpdate":"2019-06-27"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Meniere's Disease"],"interventions":[{"type":"DRUG","name":"Methylprednisolone","otherNames":[]},{"type":"DRUG","name":"Gentamicin","otherNames":[]}],"arms":[{"label":"Steroid (Methylprednisolone)","type":"EXPERIMENTAL"},{"label":"Gentamicin","type":"ACTIVE_COMPARATOR"}],"summary":"This trial aims to compare transtympanic steroids against the standard treatment (transtympanic gentamicin) in refractory unilateral Meniere's disease.","primaryOutcome":{"measure":"Vertigo Attacks","timeFrame":"6month pre-enrollment baseline, 18-24 months after initial treatment","effectByArm":[{"arm":"Steroid (Methylprednisolone)","deltaMin":16.4,"sd":12.45},{"arm":"Gentamicin","deltaMin":19.93,"sd":16.7}],"pValues":[{"comp":"OG000 vs OG001","p":"0.271"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["39973595","27865535"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Otitis media","Retinoschisis","Scwannoma","Cist"]}}